A Breath of Fresh Air: Grade 4 Pneumonitis Secondary to HER2 Antibody-Drug Conjugate Therapy Treated with Plasma Exchange

被引：0
|
作者：
Teng, Christina [1 ,2 ]
Wei, Joe Q. [1 ,2 ,3 ]
Killen, Andrew [1 ]
Thirumaran, Aricia [2 ]
Lemech, Charlotte R. [1 ,2 ,4 ]
机构：
[1] Scientia Clin Res, Randwick, NSW, Australia
[2] Prince Wales Hosp, Randwick, NSW, Australia
[3] Univ Sydney, Camperdown, NSW, Australia
[4] Univ New South Wales, Kensington, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [41] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [42] A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Vukelja, S.
    Rugo, H.
    Vogel, C.
    Borson, R.
    Tan-Chiu, E.
    Birkner, M.
    Holden, S. N.
    Klencke, B.
    O'Shaughnessy, J.
    Burris, H. A.
    CANCER RESEARCH, 2009, 69 (02) : 71S - 71S
  • [43] Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate
    Edoardo, Crimini
    Giuseppe, Curigliano
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (08) : 851 - 865
  • [44] A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy
    Krop, I
    LoRusso, P.
    Miller, K. D.
    Modi, S.
    Yardley, D.
    Rodriguez, G.
    Agresta, S.
    Zheng, M.
    Amler, L.
    Rugo, H.
    CANCER RESEARCH, 2009, 69 (24) : 795S - 795S
  • [45] DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
    Tymon-Rosario, Joan
    Bonazzoli, Elena
    Bellone, Stefania
    Manzano, Aranzazu
    Pelligra, Silvia
    Guglielmi, Adele
    Gnutti, Barbara
    Nagarkatti, Nupur
    Zeybek, Burak
    Manara, Paola
    Zammataro, Luca
    Harold, Justin
    Mauricio, Dennis
    Buza, Natalia
    Hui, Pei
    Altwerger, Gary
    Menderes, Gulden
    Ratner, Elena
    Clark, Mitchell
    Andikyan, Vaagn
    Huang, Gloria S.
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 334 - 341
  • [46] Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression
    Verheijden, Gijs
    Beusker, Patrick
    Ubink, Ruud
    van der Lee, Miranda
    Groothuis, Patrick
    Goedings, Peter
    Egging, David
    Timmers, Marco
    Dokter, Wim
    CANCER RESEARCH, 2015, 75
  • [47] SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan
    Predolini, Federica
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Altwerger, Gary
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5836 - 5845
  • [48] SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan
    Altwerger, Gary
    Masserdotti, Alice
    Pettinella, Francesca
    Zammataro, Luca
    Buza, Natalia
    Hui, Pei
    Ratner, Elena
    Litkouhi, Babak
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter
    Santin, Alessandro D.
    CANCER RESEARCH, 2017, 77
  • [49] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [50] SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
    Black, Jonathan
    Menderes, Gulden
    Bellone, Stefania
    Schwab, Carlton L.
    Bonazzoli, Elena
    Ferrari, Francesca
    Predolini, Federica
    De Haydu, Christopher
    Cocco, Emiliano
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Lopez, Salvatore
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Litkouhi, Babak
    Schwartz, Peter E.
    Goedings, Peter
    Beusker, Patrick H.
    van der Lee, Miranda M. C.
    Timmers, C. Marco
    Dokter, Wim H. A.
    Santin, Alessandro D.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1900 - 1909
12345